Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC

被引：0
|
作者：
Rothschild, S. I. [1 ]
Leger, P. [2 ]
Castellanos, E. L. [2 ]
Pillai, R. N. [3 ]
York, S. J. [2 ]
Horn, L. [2 ]
机构：
[1] Univ Spital Basel, Dept Internal Med, Med Oncol, Basel, Switzerland
[2] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91PD-PR
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [22] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER SCIENCE, 2024, 115 : 1381 - 1381
  • [23] An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021, 21 (05) : 445 - 454
  • [24] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [25] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [26] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [27] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [28] Biomarkers of response to PD-1/PD-L1 inhibition
    Vareki, Saman Maleki
    Garrigos, Carmen
    Duran, Ignacio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 116 - 124
  • [29] Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
    Yan, Ting
    Yu, Lun
    Shangguan, Dangang
    Li, Wei
    Liu, Ni
    Chen, Yun
    Fu, Yilan
    Tang, Jingyi
    Liao, Dehua
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115
  • [30] Ocular adverse events in PD-1 and PD-L1 inhibitors
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen X.
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
12345